The ability to genetically modify CD8 T cells using viral gene delivery has facilitated the development of next generation of cancer immunotherapies such as chimeric antigen receptor (CAR) T cells engineered to specifically kill tumor cells. Development of immunotherapies targeting natural killer (NK) cells have stalled in part by their resistance to viral gene delivery.
Introduction
Immunotherapies are emerging treatment options for several cancer types with CD8 T cells being the primary therapeutic target. The efficiency of viral gene delivery to activated CD8 T cells in vitro has facilitated the clinical development of chimeric antigen receptor (CAR) T cell recognizing tumor antigens such as CD19 on B cell leukemia and have recently been approved by regulatory agencies. Natural killer (NK) cells are an additional anti-tumor effector population with a clear role in limiting tumor metastasis 1, 2 and an emerging role in orchestrating inflammation and immune infiltration within solid tumors 3, 4 . NK cells are dependent on the cytokine IL-15 for their development and maturation 5 , and are educated in the periphery through the signals transduced through an array of germline activating and inhibitory receptors 6 . In addition to numerous soluble factors, it is the balance of signals transduced through these receptors that also dictates whether an NK cell engages in a cytotoxic attack against a target cell. We previously described CIS (encoded by Cish) as a potent checkpoint in NK cell activation by limiting IL-15 signal transduction 7 , while CBL-B
(Cblb) has also been proposed as an intracellular repressor of NK cell activation 8 . In addition, the group of Mantovani described IL-1R8 (Il1r8) acting as a negative regulator of IL-18 responsiveness in NK cells 9 while more recently, TIGIT (Tigit) was shown to be a major inhibitory receptor on NK cells 10 with deletion of Cish, Cblb, Il1r8 or Tigit resulting in dramatically improved NK cell-dependent anti-tumor immunity.
These pre-clinical findings highlight that NK cell anti-tumor immunity can be augmented in vivo and as such, development of NK cell immunotherapy drugs that target such pathways should be investigated. In contrast to CD8 T cells, NK cells are yet to be specifically or efficiently targeted by immunotherapy drugs in human cancer 6, 11 . A major hurdle to NK cell drug discovery has been target validation in human NK cells and this is indeed an important step given the clear disparities in NK cell phenotypes and frequencies between species. The field has therefore awaited the development of rapid and efficient gene-editing technologies such as CRISPR-Cas9 in order to perform targeted gene-editing to understand the biology on primary human NK cells. Since the initial description of CRISPR-Cas9 in mammalian cells, this technology has been used to great effect to edit genes in several immune cell lines and more recently, primary human T cells 12, 13, 14 . Editing immune cell lines has been relatively simple through lentiviral delivery of Cas9 and a gene-specific guide RNA, and has allowed genome-wide screening studies to be performed 15 . The efficacy of using similar viral delivery systems in primary immune cells has been highly cell-type specific. NK cells are notoriously difficult to infect with retro/lentiviral particles meaning that tried and tested genetic modification approaches for human T cells are not appropriate for human NK cells. For example, while IL-2 or IL-15 results in robust activation and proliferation of human NK cells, typically only around 2-3% of these cells will be infected with a lentivirus. When lentiviral multiplicity of infection (MOI) was increased from 1 to 20, the efficiency of lentivirus transduction on human NK92 cells was unchanged 16 , while other groups have increased the MOI to 150 and still only achieve ~10% transduction of human NK cells 17 . Electroporation of NK cells with mRNA or plasmid DNA is efficient for transient expression (such as anti-CD19 CAR) yet there is no evidence that transient Cas9 and sgRNA expression can lead to efficient gene editing in NK cells 17, 18 . While viral delivery of the Cas9 system to primary cells is the most utilized approach at present, delivery of recombinant Cas9 in complex with a gene-specific gRNA (together termed a ribonucleoprotein, RNP) is an emerging alternative. Reports have demonstrated that delivery of this complex can result in gene-editing in vivo 19 and highly efficient in primary immune cells, including human T cells 12, 13, 14 . With our extensive experience with primary human NK cells, we set out to firstly establish a robust and efficient DNA and viral-free CRISPR-RNP gene-editing strategy for primary human NK cells, and secondly, use this technical breakthrough to validate our recent discovery of an NK cell checkpoint in primary human NK cells. The efficiency and simplicity of our CRISPR-RNP gene-editing strategy will expedite target validation in NK cells and be transformative for immunotherapy drug development.
Methods

Cell culture & lentivirus production
Primary human NK cells were isolated from peripheral blood samples using an immunomagnetic negative selection kit (Stemcell Technologies, #17955) and expanded in G-Rex plates (Wilson Wolf, 80240M) using NK-MACS media (Miltenyi, supplemented with 5% AB human serum (Sigma-Aldrich, H6914), 1000 IU.mL of human IL-2 and 20 ng.mL human IL-15 unless otherwise stated. The SNK6 and SNK10 cell lines were a gift from (Professor Maher Ghandi, The University of Queensland) were grown in NK MACS media supplemented with 10 ng.mL human IL-15. The Daudi Burkitt's lymphoma cell line were maintained in RPMI containing 10% FBS. Cas9-containing lentivirus was produced according standard procedures using the FUCas9-mCherry plasmid described in 20 . Fresh lentivirus was used to spin-infect human T and NK cell lines on two consecutive days.
CRISPR protocols, reagents & sequencing
Optimization of electroporation conditions:
Expanded primary human NK cells (500,000 cells per well of a 16-well Nucleocuvette strip) were used to sequentially optimize the pulse code and buffer conditions for maximum viability and uptake of 70kDa FITC-labelled dextran (Sigma #46945). A range of custom buffers were created and tested, with Solution 2 + mannitol (5mM KCl, 15mM MgCl2, 15mM HEPES, 150mM Na2HPO4/NaH2PO4 (phosphate buffer), 50mM mannitol, pH 7.2) resulting in the best combination of viability and dextran-uptake (see RNP protocol below for electroporation handling technique). All electroporation experiments were carried out using the 4D Nucleofector system (Lonza).
Evaluation of the transient Cas9 expression system:
Primary human NK cells (isolated and rested overnight) and human NK cell lines were electroporated using the optimized electroporation conditions (CM137 & solution 2+mannitol) with a positive control plasmid (pmaxGFP, Lonza), dextran-FITC or a px458 vector encoding spCas9 and a sgRNA against human CD45 (vector and cloning described by 21 , sgRNA sequence in table below). Transfection efficiency (dextran), transcription/translation efficiency (pmaxGFP) and CD45-deletion efficiency (px458-CD45) were assessed by FACS 60 and 144 hours after electroporation (see RNP protocol below for electroporation handling technique). Primary human NK cells (isolated and rested overnight) and human NK cell lines were electroporated using the optimized electroporation conditions above with Cas9-RNP complexes targeting NCR1, or CISH. Cells were allowed to recover and expand for 5 days after electroporation in media containing 5ng.ml IL-15 and deletion efficiency was analyzed by western blotting, FACS or next-generation sequencing. For studies targeting NCR1, the NCR1 + and NCR1populations were subsequently FACS sorted and used in cytotoxicity assays. Next generation sequencing of CIS indel frequencies was performed using standard NGS protocols, briefly; PCR reactions containing sample gDNA and primers (listed below) flanking the CRISPR binding site were used to produce amplicons that were subjected to a second round of PCR to introduce indexes and sequencing adaptors. These 'indel libraries'
Evaluation of
were then purified (AMPure XP, Beckman Coulter), pooled for multiplexing, and sequenced on an miSeq instrument (illumina) with a target of 10-20,000 reads.
sgRNA and primer sequences used in this study: lysed in 60 µl lysis buffer with protease inhibitors for 30m ice and centrifuged at 13,000 x g for 5 minutes to clear cell debris. 10 µl of 6X sample buffer was added to 50 µl of clarified lysate, incubated at 85°C for 5 minutes and 30 µl was run on a 4-12% gel using MOPS buffer. Primary antibodies were used at a 1/1000 dilution in PBS containing 5% BSA, 0.1% Tween-20 and incubated overnight at 4°C. Secondary antibodies were used at 1/3000 in the same diluent and incubated for 1 hour at room temperature.
Cytotoxicity & proliferation assays
NK cell cytotoxicity assays were performed as previously described 22 . Briefly, target cells were loaded with calcein-AM, mixed with NK cells at various ratios, incubated for 4 hours at 37°C
and analyzed by transferring 100 µl of cell-free supernatant into opaque 96-well plates and comparing the fluorescent intensity of test wells to positive (target cells + 2% triton) and negative (target cells alone) controls. For proliferation assays, cells were plated at the indicated starting densities and absolute live cell number was quantified daily using FACS by adding enumeration beads (123count eBeads, Thermo Fisher) and a viability dye (propidium iodide).
Humanized mice
Human cord blood cells obtained from the Bone Marrow Donor Institute/Cord Blood Research
Unit (Murdoch Children' 
Results
Optimization of electroporation and protein delivery into primary human NK cells
The growing applications for adoptive T cell therapies stems from the relative ease of introducing and stably expressing synthetic genes via retro/lentiviral transduction. Genetic modification of T cells via CRISPR also exploits this ease of transduction. To compare the efficiency of human NK cell viral transduction versus human T cell transduction and the potential for genetic modification via CRISPR/Cas9, we transduced human NK (NKL) or T (Jurkat) cell lines with FUCas9-mCherry lentiviral particles (MOI = 5). Both cell lines were actively dividing in vitro, and two rounds of standard spin-infection were used. Consistent with previous work, only T cells, not NK cells were efficiently infected and stably expressed the viral gene products Cas9-mCherry ( Fig. 1a) . To investigate alternate approaches to genetically modify human NK cells we next developed a feeder-free method for primary human NK cell expansion in order to optimize electroporation conditions on a consistent source of material. NK cells are frequent in the blood and their isolation can be achieved by numerous methods including positive selection by magnetic beads and FACS sorting. We opted for a negative selection approach as this typically yields >95% purity (NKp46 + CD56 + CD3 -) with minimal loss of viability as is often associated with FACS sorting. NK cells were then seeded at a density of 2e6 cells.cm 2 in either G-rex 24 or 6 well plates using NK-MACS media (Miltenyi) supplemented with 1000 IU.mL IL-2, 20ng.mL IL-15 and 5% AB+ human serum. Half the culture media was removed and replaced with fresh media every third day until desired number of NK cells was achieved ( Fig. 1b) . Numerous methods exist to deliver small molecules and nucleic acids into cells, however delivery of large protein complexes is most efficient when the cell surface is physically disrupted to allow the passive diffusion of such molecules into the cells. Both mechanical disruption and electroporation-based technologies have been adapted to introduce CRISPR RNPs into mammalian cells, though electroporation has emerged as the predominant platform due to the widespread availability of these devices and adaptability for use in in-vivo settings 19 . However, one of the major hurdles in the NK cell field has been the relatively poor survival of NK cells post-electroporation. We therefore next establish electroporation conditions for human NK cells that would maximize their viability and uptake of large molecules using the widely-available Lonza 4D nucleofector device ( Fig. 1b) .
Beginning with the manufacture's recommendations, we set out to optimize the electrical pulse applied to the cells, or "pulse-code", using the manufacturer's own P3 nucleofection buffer ( Fig. 1c) . The recommended read-out for such optimizations is the nucleofection of a GFPencoding plasmid to determine the efficacy of nucleofection. However, given the size of recombinant Cas9 (approximately 160kDa) and the fact that RNP-mediated editing does not require transcription from a plasmid template we decided to optimize with a fluorescentlylabelled high molecular weight dextran. Pulse code DN100 resulted in the maximum up-take of FITC-dextran (~95%), yet viability was only ~40% (Fig. 1c) . We next tested whether alternate buffers could further improve NK cell viability and therefore created a panel of homemade buffers to compare to the P3 standard. Our home-made buffer "Sol. 2 + mannitol"
improved NK cell viability (>60%) without compromising FITC-Dextran uptake and was therefore adopted as our standard buffer to for primary NK cell electroporation ( Fig. 1d) . We then re-optimized the pulse-codes using our Sol. 2 + mannitol buffer and found that pulsecode CM137 was optimal resulting in >80% NK cell viability and FITC-Dextran uptake and Sol. 2 + mannitol/pulse-code CM137 was adopted as our human NK cell electroporation conditions ( Fig. 1d ).
Transient transfection of Cas9 RNP but not Cas9-expressing plasmid results in efficient gene editing in human NK cells
A recent report demonstrated that T cells could be efficiently gene-edited by simply introducing plasmids that contain Cas9 and the gRNA (transient transfection) 24 , and if applicable to NK cells, would represent the most rapid and cost-effective method of geneediting. We therefore cloned one of our validated guides against human CD45 (guide #61)
into the Px458 'all-in-one' vector 21 that encodes Cas9 gene, eGFP and the sgRNA. A vector encoding eGFP alone (pmaxGFP) was used as a positive control for transient gene expression. 60 and 144 hours following electroporation of primary human NK cells with these plasmids, we measured NK cell expression of GFP and CD45 (targeted for deletion by PX458). While primary human NK cells were found to expressed GFP (25-35%) following electroporation of pmaxGFP, we failed to detect GFP expression using Px458 and therefore unsurprisingly no deletion of CD45 was observed ( Fig. 2a) . The fraction of GFP expressing cells was significantly higher (50-80%) when human NK cell lines (SNK6, SNK10) where electroporated with pmaxGFP, yet still no Cas9-GFP nor CD45 deletion was observed in these lines ( Fig. 2a) . Thus, we concluded that primary human NK cells poorly transcribe genes from plasmid templates, which is further diminished when required to transcribe large genes such as Cas9 in the case of Px458.
Considering the difficulty of inducing Cas9 expression within NK cells, we opted for the delivery of the fully assembled "ready-to-go" ribonucleoprotein (RNP) complexes as this has recently been shown to efficiently edit primary human T cells (Fig. 2b) 13, 14 . RNP complexes were created by incubating fully-synthetic sgRNA guides (identical in sequence to those used in the expression was found to be stable (Fig. 2c) suggesting homo-and heterozygous human NK cells can be generated and that Cas9-RNP is an efficient method to genetically modify large numbers of primary human NK cells.
Using Cas9 RNP to validate genetically-modified murine NK cell data in human NK cells
The NCR-family of NK cell activating receptors includes NKp46, NKp44, NKp30 (encoded by Ncr1, Ncr2, Ncr3) in humans but only NKp46 exists in mice 25 . NKp46 is ubiquitously expressed on mature NK cells where it defines the lineage in both species and can trigger IFNg production when cross-linked 7 . NKp46-null murine NK cells (Ncr1 gfp/gfp ) display impaired ability to kill NKp46-ligand expressing tumor cells in vitro 26, 27 . To investigate if optimal human NK cell cytotoxicity against tumor cells also requires NKp46, we deleted NCR1 from freshly isolated primary human NK cells from two independent donors using Cas9-RNP with two distinct gRNA against NCR1. Deletion efficiency ranged from 8-23%, with both gRNA having similar NCR1 deletion efficiency (loss of NKp46 expression; Fig. 3a) . We next FACS sorted NKp46 + and NKp46 − NK cells from each donor and directly compared their cytotoxicity against Daudi cells (human Burkitt B cell lymphoma). Daudi cells were chosen due to their susceptibility to lysis by allo-NK cells and because they stained highly for human NKp46-Fc indicating they express putative NKp46 ligands (Fig. 3b) . Consistent with the murine data, we found human NKp46 -NK cells were clearly inferior to NKp46 + counterparts from the same donor at lysing Daudi cells in vitro (Fig. 3c) . Given the low deletion efficiency of NCR1 (% NKp46 -) in freshly isolated primary human NK cells, we next investigated if highly metabolic, activated and proliferating primary human NK cells were a more efficient target population for NCR1 deletion. NK cells isolated from donor 2 (Fig. 3a) were expanded in G-Rex flasks for 14 days as in Fig. 1 . Using the identical gNCR1/g543 as in Fig. 3a , we observed significantly higher NCR1-deletion using expanded primary human NK cells with 85% NKp46 -NK cells (5µl gRNA; Fig. 3d ) compared to 23.7% NKp46 -NK cells using freshly NK cells from the same donor (Fig. 3a) . We also observed that NCR1 gene-editing efficiency could be modulated by titrating the amount of gRNA used in the RNP complex and including a non-homologous DNA enhancer as previously shown 28 (Fig. 3d) . Taken together, these data support a conserved role for NKp46 in augmenting NK cell cytotoxicity upon detection of NKp46-ligands on tumor cells and highlight the utility of Cas9-RNP in validating murine NK cell biology in humans.
Validating CISH as an immune checkpoint in human NK cells using Cas9-RNP
Work from our group and others over the past 10 years has established the cytokine IL-15 is essential for most facets of NK cell biology including survival, homeostasis, differentiation and activation 1, 7, 29 . We recently discovered that CIS (encoded by Cish) acts as a checkpoint in Fig. 4a and data not shown). Both single g26 and g57 showed similar efficiency for CISH deletion and SNK10 cells electroporated in the absence of Cas9-RNP (SNK10-Mock) served as negative controls. We next probed SNK10+g57 cells for IL-15 hyper-responsiveness compared to SNK10-Mock.
Both phospho-JAK1 and phospho-STAT5 were readily induced by IL-15 from 15 minutes, indicating the IL-15 pathway is intact in SNK10 cells (Fig. 4b) . Consistent with our murine findings in Cish -/-NK cells, SNK10+g57 cells displayed clearly enhanced phospho-JAK1 and phospho-STAT5 following IL-15 stimulation compared to SNK10-Mock. CIS protein was induced in SNK10-Mock cells at 60 minutes following IL-15 stimulation, consistent with murine NK cells and the ~30kDa CIS protein was absent from SNK10-g57 cells while a weak ~35kDa CIS protein band could be detect at 120 minutes inline with the ~10% unedited cells in the pool (Fig. 4b) . As previously documented for Cish −/− murine NK cells, in vitro culture in 5ng.mL of IL-15 resulted in significantly greater SNK10-g57 cell proliferation compared to SNK10-Mock controls (Fig. 4c) . We next confirmed these findings in primary human NK cells using the identical protocol. NK cells from peripheral blood of 4 healthy human donors were isolated, cultured in IL-15 overnight and electroporated in the presence of Cas9+g26 (g26-RNP) or g26 alone (Mock-RNP). NK cells were then cultured in 5ng.mL IL-15 for 5 days. In each of the 4 donors, g26-RNP resulted in a 2-3 fold increase in NK cell numbers compared to Mock-RNP from the same donor ( Fig. 5a ) and this was in part due to enhanced proliferation (Fig. 5b) .
Being an intracellular protein that is rapidly induced then degraded following IL-15 stimulation, CIS levels are difficult to quantitate using conventional techniques such as western blotting and intracellular FACS, and this is complicated further by the fact that two CIS protein isoforms (~30kDa/35kDa) are detected by the available anti-CIS polyclonal antibodies. g26-RNP results in loss of both CIS isoforms (Fig. 4a ) therefore we used NGS to quantify the frequency of DNA mutation (indels) caused by Cas9+g26 around the CISH target sequence. A range of idels were introduced by g26-RNP in primary human NK cells with the average indel frequency being 63.75% and ranging from 45-80% indel frequency across the 4 donors ( Fig. 5c) .
Furthermore, primary human NK cells edited by g26-RNP, g57-RNP or both all displayed enhanced cytotoxicity towards Daudi B lymphoma cells compared to Mock-RNP control cells ( Fig. 5d) opted to perform these experiments using the single g26 so that indel frequency could be easily estimated with NGS throughout the experiment. Using the same electroporation conditions as primary human NK cells, we were able to achieve 43% editing efficiency in freshly-isolated human cord blood CD34 + cells. This result was encouraging for only a single guide and the fact that CIS is not highly expressed in CD34 cells, an obvious impediment to efficient gene editing in cells 30 . These pool of partially CISH-deleted/g26-RNP cells or Mock-RNP cells were then injected into the facial vein of lethally-irradiated 3-day old BRGS mice 23 and allowed to reconstitute for 12 weeks (Fig. 5e) . Similar to our data from Cish −/− mice, there was no obvious accumulation of NK cells in mice that received g26-RNP CD34 + cells (Fig.5f) , and NGS sequencing of the resulting NK cells showed a similar indel frequency to the starting g26-RNP CD34 + cord blood progenitors (data not shown) suggesting CIS is not playing a major role in human NK cell development and homeostasis. The NK cell population reconstituted from g26-RNP edited CD34 + cord blood progenitors phenocopied that of human peripheral blood NK cells as we have previously shown 31 and did not differ from Mock-RNP controls (data not shown). We next interrogated the IL-15 receptor signaling of g26-RNP CD34 + cord blood progenitor-derived NK cells in vitro. We isolated human NK cells from the spleens of two g26-RNP and two Mock-RNP humanized mice and subjected them to an IL-15 proliferation assay in vitro. Similar to the data observed in g26-RNP primary human NK cells and g57-RNP SNK10 cells, the NK cells derived from g26-RNP humanized mice were able to proliferate significantly greater in response to IL-15 compare to their Mock-RNP counterparts ( Fig. 5g) . Furthermore, the indel frequency increased from 43% upon NK cell isolation from the g26-RNP humanized mouse spleen to 75% following the 7-day proliferation assay (data not shown). Taken together, these data demonstrate the efficiency of gene targeting in human NK cells and the validates the role of CIS as a potent negative regulator of IL-15 signaling in human NK cells.
Discussion
Here we describe, for the first time, an effective approach for genetic manipulation of primary human NK cells using CRISPR-Cas9 RNP and demonstrate that our recent discovery of an NK cell checkpoint in mice is also a conserved and valid target in human NK cells. To date, there have been few examples of genetically-engineered primary human NK cells largely due to poor infection rates with viral gene-transfer systems and difficulties in culturing primary human cells to significant numbers. Recent advances in viral pseudotyping and antagonizing intracellular anti-viral pathways have improved infection rates and opened the door for application such as CAR-NK cell products 16 . A concern from lentiviral modification of human NK cells is mutagenesis caused by random insertion of viral genes into the genome given the high viral titers (>150 MOI) required for infection 17 . In addition, viral delivery and expression of gene-editing machinery require the target cells to be cultured for several days before the desired gene is edited, potentially losing the naïve phenotype of the target cell. A recent study showed that simply delivering plasmids that encode the gene editing machinery could efficiently target genes in T cells 24 , however our data suggest that even highly-activated NK cells are inefficient at transcribing the required genes from large plasmid templates to result in Cas9-mediated editing. It is worth noting that pMAX-GFP vector uses a CMV promoter and at 3486bp is considerably smaller than the Px458 (9300bp) which uses a Cbh promoter.
We therefore set out to establish whether direct delivery of Cas9-RNP complexes directly into freshly isolated human NK cells could rapidly and efficiently edit certain genes. An additional benefit of using NLS-tagged Cas9 RNP is that the delivery method does not depend upon successful nuclear delivery, as the complex can be easily transported into the nucleus 19 . Upon entry into the nucleus, the Cas9 RNP rapidly binds DNA and begins scanning for the regions complementary to the guide RNA. The kinetics of this editing process have been described to take between 2-12 hours 32 , meaning that primary human NK cells could be easily edited within a day to study their function.
The cancer immunotherapy revolution over the past 10 years has seen rising interest in targeting NK cells given their spontaneous ability to detect and kill stressed/transformed cells 6 .
Furthermore, NK cells are emerging as key drivers of dendritic cell infiltration and optimal priming of IFN + and TNFa + CD8 T cells 3, 4, 10 . Yet, despite our best efforts, cancer immunotherapy drugs that exploit the innate anti-tumor functions of NK cells are yet to have a positive impact on cancer outcomes. This is in part due to the vast differences between mouse and human NK cell frequencies and phenotypes in vivo and due to the difficulty in validating if therapeutic targets derived from murine genetic knockout studies hold true for human NK cells. To this end, our CRISPR-Cas9 RNP approach detailed here will be transformative for NK cell immunotherapy drug development and basic understanding of human NK cell biology. CRISPR-Cas9 RNP now makes ease of rapid gene editing in primary human NK cells overcoming this current barrier to target pathway validation. To this end, we investigated two pathways known to regulate murine NK cell anti-tumor function in human NK cell lines and primary human NK cells. NKp46 is a transmembrane receptor that signaling via CD3ζ and FcεRIγ to recruit multiple ITAM-containing proteins. Cross-linking NKp46 with antibodies results in IFNg production, which is augmented by IL-15 signaling 7 . NKp46-null mice display impair anti-metastatic responses in vivo and impaired cytotoxicity in vitro to tumor cells that bind NKp46-Fc and presumable express putative NKp46 ligands 27, 33, 34 . Using Cas9-RNP+gNcr1, we were able to delete NKp46 on a subset of primary human NK cells and validate that NKp46 expression confers optimal NK cell cytotoxicity towards NKp46-ligand expressing Daudi B lymphoma cells. Deletion of genes for cell-surface proteins was thus clearly feasible, and the ability to FACS sort for gene-edited cells makes cell surface proteins practical targets for validation using this method. We next addressed the feasibility to delete the intracellular immunotherapy drug target CIS using Cas9-RNP+gCish. Cish has been published by multiple groups to limit IL-15 and TCR signaling in murine NK and T cells, ultimately dampening anti-tumor responses 7, 35, 36 . Cish was efficiently deleted in human NK cells (45-80% indels in primary cells; 85-93% indels in NK cell lines) yet the inability to sort on Thus, while primary human T cells can be genetically modified by several approaches including lenti/retrovirus transduction, transient transfection and Cas9-RNP 13, 24 , the latter approach is the only viable approach for large-scale genetic modification of primary human NK cells. With further optimization of guide sequences, recombinant Cas9 source and multiplexing of distinct guides, it is likely that most genes will be able to be deleted at a high enough efficiency to concinving conclude their role in human NK cells. Our detailed technical report of Cas9-RNP in human NK cells lends itself to immunotherapy drug discovery including rapid gene-editing of patient-derived or allo-NK cellular therapy products meaning undruggable pathways can be efficiently targeted for personalized immunotherapy. 
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